United Pharmaceuticals provides scientifically rigorous ligand binding assay services designed to support accurate decision-making throughout the drug development lifecycle. Our bioanalytical teams deliver customized immunoassay solutions that meet the technical, operational, and regulatory demands of modern pharmaceutical programs.
By integrating robust assay design with scalable laboratory workflows, we ensure consistent performance from early research through late-stage clinical development. Our ligand binding assays are developed to address complex biological questions while maintaining strict compliance with global regulatory expectations and internal quality systems.
Our experienced bioanalytical scientists apply ligand binding assay methodologies across multiple stages of development, delivering reliable and reproducible data for a broad range of therapeutic areas, including metabolic disorders, neurological conditions, oncology, genetic diseases, and autoimmune indications.
We routinely work with diverse biological matrices such as plasma, serum, cerebrospinal fluid, and tissue samples obtained from multiple animal models and human studies. This flexibility allows United Pharmaceuticals to design fit-for-purpose assay strategies tailored to each program’s scientific objectives and regulatory pathway.
United Pharmaceuticals offers a comprehensive portfolio of ligand-binding assay formats validated to support preclinical studies through Phase III clinical trials. Each assay is optimized to achieve high sensitivity, specificity, accuracy, and reproducibility.
All assay development and validation activities are conducted in accordance with Good Laboratory Practice and Good Clinical Practice guidelines. Our processes are designed to meet the requirements of global regulatory authorities, including the Food and Drug Administration, European Medicines Agency, and International Council for Harmonisation.
Successful pharmaceutical development requires bioanalytical methods that are adaptable, reliable, and scientifically defensible. United Pharmaceuticals supports drug development programs from preclinical research through clinical trials by combining advanced analytical technologies with deep scientific expertise.
Our teams customize ligand binding assay methodologies based on molecule type, therapeutic indication, study phase, and regulatory strategy. This tailored approach ensures that bioanalytical data generated at each stage are relevant, interpretable, and suitable for regulatory submission.
United Pharmaceuticals delivers precise and reproducible ligand binding assay data across all phases of drug development. Our services can be structured to support individual studies or integrated development programs, providing flexibility while maintaining consistent quality and compliance.
Key strengths include:
Our bioanalytical teams work in close collaboration with sponsors to design ligand-binding assay solutions that support scientific objectives and regulatory success.